Codexis to share RNA manufacturing advances at TIDES USA

Codexis (NASDAQ: CDXS) will present RNA manufacturing advances at TIDES USA, May 11–14 in Boston.

Rhea-AI Summary

Codexis (NASDAQ: CDXS) will present RNA manufacturing advances at TIDES USA, May 11–14 in Boston. Presentations cover ECO Synthesis® platform results on phosphorothioate stereochemistry control, ligation efficiency, process performance, and sustainability. Codexis will host a panel and maintain a booth (821) during the conference.

Argus Apr 29 session

-0.35% close to close Open Argus

Details

News Market Reaction – CDXS

In the Apr 29 session, CDXS declined 0.35%, reflecting a mild negative market reaction.

Data tracked by StockTitan Argus on the day of publication.

Market Context

This announcement spotlights Codexis’s ECO Synthesis platform through multiple TIDES USA presentatio...

Analysis

This announcement spotlights Codexis’s ECO Synthesis platform through multiple TIDES USA presentations, emphasizing RNAi manufacturing scalability, phosphorothioate stereochemistry control and ligation efficiency. It continues a series of updates linking ECO Synthesis to siRNA production and industry engagement. Investors evaluating this news may focus on how these technical advances translate into additional contracts, revenue beyond prior ECO Synthesis agreements, and further regulatory engagement milestones, as flagged in earlier FY 2025 and platform-related disclosures.

Key Figures

TIDES USA dates: May 11–14 Spotlight time: May 14, 8:30–9:00 a.m. TIDES Talk time: May 13, 10:25–10:35 a.m. +3 more

TIDES USA dates

May 11–14

Conference dates at Hynes Convention Center, Boston

Spotlight time

May 14, 8:30–9:00 a.m.

Controlling phosphorothioate stereochemistry session

TIDES Talk time

May 13, 10:25–10:35 a.m.

Superior ligation solutions presentation

Conference presentation time

May 13, 4:15–4:45 p.m.

Advancing sustainability in oligonucleotide manufacturing

Booth number

821

Codexis presence on TIDES USA exhibit floor

Panel date

Tuesday, May 12

Expert panel on stereochemistry in RNAi manufacturing

Historical Context

5 past events · Latest: Apr 23

5 events

1. Apr 23

   Earnings date notice

   24h Move

   +2.0%

   Announcement of Q1 2026 earnings release date and conference call details.

2. Mar 11

   Earnings results

   24h Move

   +34.6%

   Q4 and FY 2025 results with ECO Synthesis momentum and 2026 revenue guidance.

3. Mar 04

   Platform agreement

   24h Move

   +10.2%

   Agreement to manufacture 50 g siRNA using ECO Synthesis for a preclinical program.

4. Feb 25

   Earnings date notice

   24h Move

   +1.4%

   Scheduling of Q4 and FY 2025 results release and webcast information.

5. Feb 17

   Conference participation

   24h Move

   +0.8%

   Participation in TD Cowen health care conference and planned fireside chat.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Key Terms

rna, rnai, phosphorothioate stereochemistry, oligonucleotide, +1 more

5 terms

rna medical

"share RNA manufacturing advances at TIDES USA, held May 11–14"

RNA (ribonucleic acid) is a natural molecule that carries instructions from a cell’s DNA to make proteins and can also act as a tool to turn genes on or off; think of it as a messenger or software that tells biological machinery what to build or modify. It matters to investors because RNA-based tests and therapies can create new markets or change treatment costs and regulatory risk, so progress or setbacks in RNA science often drive valuation swings in biotech companies.

rnai medical

"As RNAi therapies expand into larger indications, manufacturing scalability"

RNAi, short for RNA interference, is a natural cellular process that acts like a mute button for specific genes by using small RNA molecules to stop a target gene from producing its protein. For investors, RNAi matters because it is the underlying mechanism behind a class of precision medicines that can silence disease-causing genes, offering high potential returns but also scientific, regulatory and manufacturing risks unique to novel drug platforms.

phosphorothioate stereochemistry medical

"advances in controlling phosphorothioate stereochemistry, improved ligation efficiency"

Phosphorothioate stereochemistry describes the three-dimensional arrangement at a modified link in synthetic DNA/RNA drugs where one oxygen is swapped for sulfur, producing mirror-image forms like left- and right-hand versions of a glove. Those mirror-image forms can alter a drug’s stability, activity and side-effect profile and complicate manufacturing and quality control, so they affect development risk, regulatory review, production cost and commercial reliability for investors.

oligonucleotide medical

"Challenges and Innovations in Oligonucleotide ManufacturingStefan Lutz, PhD."

A short chain of DNA or RNA molecules used to target, detect, or change specific genetic messages inside cells; think of it as a tiny, programmable instruction or zip code that can find and bind one exact genetic sentence. Investors care because oligonucleotides are the active ingredient in a growing class of precision therapies and diagnostics, so their success, manufacturing cost, and regulatory approval can directly affect a company's value and future revenue.

sirna medical

"sustainability advantages of siRNA manufacturing approaches. Codexis’ technical experts"

Small interfering RNA (siRNA) is a short strand of genetic material that binds to and destroys the messenger RNA that carries instructions for making a specific protein, effectively switching that gene off. Investors care because siRNA is a platform for precise medicines: successful trials or approvals can create high-value drugs, while delivery challenges, manufacturing complexity, patent positions and regulatory risk can sharply affect a biotech company's prospects.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

REDWOOD CITY, Calif., April 29, 2026 (GLOBE NEWSWIRE) -- Codexis, Inc. (NASDAQ: CDXS) a leading provider of enzymatic solutions for efficient and scalable therapeutics manufacturing, will present new data on ECO Synthesis® Manufacturing Platform and provide an update on regulatory engagement for its enzymatic platform at TIDES USA, held May 11–14 at the Hynes Convention Center in Boston.

As RNAi therapies expand into larger indications, manufacturing scalability, maintaining process control and delivering high-quality product is critical. Codexis will present data demonstrating advances in controlling phosphorothioate stereochemistry, improved ligation efficiency and process performance, alongside the sustainability advantages of siRNA manufacturing approaches.

Codexis’ technical experts will present at three sessions during the conference:

Spotlight Presentation:
Controlling Phosphorothioate Stereochemistry: Challenges and Innovations in Oligonucleotide Manufacturing
Stefan Lutz, PhD., Chief Scientific Officer
Thursday, May 14, 8:30–9:00 a.m.

TIDES Talk:
Superior Ligation Solutions for Scalable RNA Manufacturing
Derek Gauntlett, Vice President, Development
Wednesday, May 13, 10:25–10:35 a.m.

Conference Presentation:
Advancing Sustainability through Innovation in Oligonucleotide Manufacturing
David Entwistle, PhD., Senior Director, Program and Pipeline Management
Wednesday, May 13, 4:15–4:45 p.m.

In addition to Codexis’ talks and booth (821) presence at TIDES USA, Codexis will also host an expert panel discussion and networking event, “Stereochemistry in RNAi Manufacturing: Signal or Noise?”, on Tuesday, May 12. This panel will explore the growing industry focus on stereochemical control, manufacturing options, and its implications for therapeutic performance, and product quality. Panellists include:

• John Maraganore, PhD., Founder and Former CEO at Alnylam
• Fred Fleitz, PhD., SVP of CMC and Development Chemistry at Arrowhead Pharmaceuticals
• Alison Moore, PhD., President and CEO at Codexis
• Raman Sehgal, Entrepreneur, and Host of the Molecule to Market Podcast

About Codexis, Inc.

Codexis is a leading provider of enzymatic solutions for efficient and scalable therapeutics manufacturing, leveraging its proprietary CodeEvolver^® technology platform to discover, develop and enhance novel, high-performance enzymes. Codexis enzymes solve for real-world challenges associated with small molecule pharmaceuticals manufacturing and nucleic acid synthesis. The Company is currently developing its proprietary ECO Synthesis manufacturing platform to enable the scaled manufacture of RNAi therapeutics through an enzymatic route. Codexis’ unique enzymes can drive improvements such as higher yields, reduced energy usage and waste generation, improved efficiency in manufacturing and greater sensitivity in genomic and diagnostic applications. For more information, visit codexis.com.

For investor inquiries:
Georgia Erbez
(650) 421-8100
ir@codexis.com

For media inquiries:
aranda@ramarketingpr.com

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What will Codexis (CDXS) present at TIDES USA May 11–14, 2026?

Codexis will present technical data on its ECO Synthesis® manufacturing platform and process performance improvements. According to Codexis, talks address stereochemistry control, improved ligation efficiency, and sustainability in siRNA and oligonucleotide manufacturing.

When and where are Codexis (CDXS) speaking sessions at TIDES USA 2026?

Codexis speakers appear across May 13–14, 2026 at the Hynes Convention Center in Boston. According to Codexis, sessions include May 13 (10:25 a.m., 4:15 p.m.) and May 14 (8:30 a.m.) with multiple technical presentations.

Who are the Codexis presenters and panelists at TIDES USA 2026?

Presenters include Stefan Lutz, Derek Gauntlett, and David Entwistle; panelists include Alison Moore and industry guests. According to Codexis, John Maraganore and Fred Fleitz are among invited panel participants discussing stereochemistry in RNAi manufacturing.

What topics will Codexis' expert panel discuss on May 12, 2026?

The panel will explore stereochemical control, manufacturing options, and implications for therapeutic performance and product quality. According to Codexis, the discussion aims to evaluate industry trends and technical challenges in RNAi manufacturing.

Where can investors find Codexis at TIDES USA and how can they engage?

Codexis will have a booth at 821 and host a networking panel during the conference. According to Codexis, attendees can visit booth 821, attend presentations, and join the May 12 panel event for technical dialogue.